Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treatment Containing an Anti-CTLA-4 Monoclonal Antibody CheckMate 172: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 172

Trial Profile

A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treatment Containing an Anti-CTLA-4 Monoclonal Antibody CheckMate 172: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 172

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Malignant melanoma; Uveal melanoma
  • Focus Adverse reactions
  • Acronyms CheckMate 172
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 30 Sep 2019 Results as off 23rd march 2018, evaluating safety and overall survival results in challenging subgroups that received nivolumab in CheckMate 172 published in the European Journal of Cancer
    • 12 Aug 2019 Results (n=1008) assessing safety and efficacy of nivolumab in patients with melanoma, published in the European Journal of Cancer
    • 19 Apr 2019 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top